Liver cancer drug shows promise in Late-Stage patients

NCT ID NCT05117957

Completed Disease control Sponsor: Bo Hyun Kim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study tested the drug sorafenib in 50 adults with advanced liver cancer that had worsened after at least one prior treatment. Participants took sorafenib daily to see if it could slow tumor growth and improve survival. The trial measured how long patients lived without their cancer getting worse and monitored side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sorafenib (a targeted cancer drug taken as a pill)
What this could lead to: If successful, this could provide a treatment option for patients with advanced liver cancer who have not responded to other therapies.
What could go wrong: This is a small, early-phase trial (50 participants) with no control group, so results may not be definitive. Sorafenib can cause side effects like fatigue, diarrhea, and skin reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

National Cancer Center, Korea

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.